CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 87.41% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Scan to Download iOS&Android APP

Trade Achieve Life Sciences, Inc. - ACHV CFD

4.91
1.64%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.27
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.0308 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.0308%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.0308 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.0137%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 4.87
Open* 4.88
1-Year Change* -1.21%
Day's Range* 4.79 - 4.79
52 wk Range 2-8.61
Average Volume (10 days) 0.19884
Average Volume (3 months) 1.27711
Market Cap 27.9669
P/E Ratio N/A
Shares Outstanding 9710750
Revenue N/A
EPS -3.98993
Dividend (Yield %) N/A
Beta 1.20343
Next Earnings Date Mar 8, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jun 29, 2022 4.91 0.03 0.61% 4.88 4.95 4.79
Jun 28, 2022 4.87 -0.23 -4.51% 5.10 5.20 4.85
Jun 27, 2022 5.10 0.02 0.39% 5.08 5.14 4.91
Jun 24, 2022 5.15 0.05 0.98% 5.10 5.24 5.00
Jun 23, 2022 5.06 -0.08 -1.56% 5.14 5.32 5.06
Jun 22, 2022 5.12 0.03 0.59% 5.09 5.37 5.09
Jun 21, 2022 5.29 -0.24 -4.34% 5.53 5.63 5.28
Jun 17, 2022 5.49 0.01 0.18% 5.48 5.69 5.34
Jun 16, 2022 5.48 -0.35 -6.00% 5.83 5.83 5.45
Jun 15, 2022 5.90 -0.05 -0.84% 5.95 6.07 5.82
Jun 14, 2022 5.94 -0.13 -2.14% 6.07 6.12 5.87
Jun 13, 2022 5.99 -0.22 -3.54% 6.21 6.25 5.92
Jun 10, 2022 6.39 -0.16 -2.44% 6.55 6.55 6.39
Jun 9, 2022 6.57 0.06 0.92% 6.51 6.63 6.51
Jun 8, 2022 6.58 0.19 2.97% 6.39 6.60 6.39
Jun 7, 2022 6.55 0.09 1.39% 6.46 6.62 6.39
Jun 6, 2022 6.47 -0.14 -2.12% 6.61 6.71 6.46
Jun 3, 2022 6.63 -0.03 -0.45% 6.66 6.74 6.56
Jun 2, 2022 6.60 0.04 0.61% 6.56 6.63 6.56
Jun 1, 2022 6.54 -0.23 -3.40% 6.77 6.80 6.42

Achieve Life Sciences, Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total revenue 5.062 0 0 0 0 0
Revenue 5.062
Total Operating Expense 26.254 5.16 12.813 16.528 14.75 33.094
Selling/General/Admin. Expenses, Total 8.933 3.531 6.945 6.854 7.868 9.128
Research & Development 14.788 3.101 5.868 9.674 6.882 23.966
Unusual Expense (Income) 2.533 -1.472 0 0
Operating Income -21.192 -5.16 -12.813 -16.528 -14.75 -33.094
Interest Income (Expense), Net Non-Operating 0.203 0.021 0.171 0.17 0.069 0.017
Other, Net 0.86 0.115 -0.045 -0.037 -0.049 -0.075
Net Income Before Taxes -20.129 -13.634 -12.687 -16.395 -14.73 -33.152
Net Income After Taxes -20.129 -10.583 -12.687 -16.395 -14.73 -33.152
Net Income Before Extra. Items -20.129 -10.583 -12.687 -16.395 -14.73 -33.152
Net Income -20.129 -10.583 -12.687 -16.395 -14.73 -33.152
Income Available to Common Excl. Extra. Items -20.129 -10.583 -12.687 -16.395 -14.73 -33.152
Income Available to Common Incl. Extra. Items -20.129 -10.583 -12.687 -16.395 -14.73 -33.152
Diluted Net Income -20.129 -10.583 -12.687 -16.395 -14.73 -33.152
Diluted Weighted Average Shares 0.01361 0.02397 0.17551 0.41232 2.71891 8.11984
Diluted EPS Excluding Extraordinary Items -1478.62 -441.473 -72.2861 -39.7628 -5.41761 -4.08284
Diluted Normalized EPS -1292.55 -247.927 -72.2861 -39.7628 -5.41761 -4.08284
Gain (Loss) on Sale of Assets -8.61 0 0
Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022
Total revenue 0 0 0 0 0
Total Operating Expense 7.984 11.302 6.693 7.115 7.226
Selling/General/Admin. Expenses, Total 2.342 2.075 2.102 2.609 2.838
Research & Development 5.642 9.227 4.591 4.506 4.388
Operating Income -7.984 -11.302 -6.693 -7.115 -7.226
Interest Income (Expense), Net Non-Operating 0.008 0.003 0.003 0.003 -0.353
Other, Net -0.023 -0.012 -0.001 -0.039 0.006
Net Income Before Taxes -7.999 -11.311 -6.691 -7.151 -7.573
Net Income After Taxes -7.999 -11.311 -6.691 -7.151 -7.573
Net Income Before Extra. Items -7.999 -11.311 -6.691 -7.151 -7.573
Net Income -7.999 -11.311 -6.691 -7.151 -7.573
Income Available to Common Excl. Extra. Items -7.999 -11.311 -6.691 -7.151 -7.573
Income Available to Common Incl. Extra. Items -7.999 -11.311 -6.691 -7.151 -7.573
Diluted Net Income -7.999 -11.311 -6.691 -7.151 -7.573
Diluted Weighted Average Shares 6.13182 7.3906 9.45224 9.4682 9.45875
Diluted EPS Excluding Extraordinary Items -1.30451 -1.53046 -0.70787 -0.75527 -0.80063
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -1.30451 -1.53046 -0.70787 -0.75527 -0.80063
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total Current Assets 26.927 5.908 15.537 17.334 36.975 44.594
Cash and Short Term Investments 25.463 5.284 14.604 16.664 35.853 43.022
Cash 1.8
Cash & Equivalents 11.931 5.284 9.515 16.664 35.853 43.022
Short Term Investments 11.732 5.089
Total Receivables, Net 0.51 0.009 0.007 0.008 0.153
Accounts Receivable - Trade, Net 0.478 0.009 0.007 0.008
Prepaid Expenses 0.954 0.393 0.926 0.662 1.122 1.419
Total Assets 27.47 9.892 19.084 21.078 40.298 47.516
Property/Plant/Equipment, Total - Net 0.258 0.059 0.035 0.386 0.188 0.079
Property/Plant/Equipment, Total - Gross 1.707 1.144 0.755 0.986 0.82 0.366
Accumulated Depreciation, Total -1.449 -1.085 -0.72 -0.6 -0.632 -0.287
Other Long Term Assets, Total 0.285 0.359 0.168 0.237 0.237 0.168
Total Current Liabilities 8.455 2.013 3.27 2.869 2.935 4.55
Accounts Payable 2.121 0.213 0.144 0.859 0.332 0.841
Accrued Expenses 6.045 1.773 3.126 2.01 2.603 3.709
Notes Payable/Short Term Debt 0 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.057 0.027
Other Current Liabilities, Total 0.232 0
Total Liabilities 8.504 2.013 3.282 3.028 3.012 19.474
Total Long Term Debt 0.049 0 0 0 0 14.92
Long Term Debt 0.049 14.92
Total Equity 18.966 7.879 15.802 18.05 37.286 28.042
Common Stock 0.029 0.012 0.018 0.041 0.076 0.079
Additional Paid-In Capital 213.239 20.556 41.161 63.709 97.64 121.545
Retained Earnings (Accumulated Deficit) -196.942 -12.694 -25.381 -45.704 -60.434 -93.586
Other Equity, Total 2.64 0.005 0.004 0.004 0.004 0.004
Total Liabilities & Shareholders’ Equity 27.47 9.892 19.084 21.078 40.298 47.516
Total Common Shares Outstanding 0.01365 0.05978 0.33606 1.47426 6.11174 9.45354
Other Current Assets, Total 0.222 0
Goodwill, Net 1.034 1.034 1.034 1.034 1.034
Intangibles, Net 2.532 2.31 2.087 1.864 1.641
Deferred Income Tax 0
Other Liabilities, Total 0.012 0.159 0.077 0.004
Total Preferred Shares Outstanding 0.00058 0.00112 0
Redeemable Preferred Stock 0 0
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 30.439 42.431 34.733 44.594 37.692
Cash and Short Term Investments 29.637 42.001 33.312 43.022 36.337
Cash & Equivalents 29.637 42.001 33.312 43.022 36.337
Prepaid Expenses 0.802 0.43 1.27 1.419 1.355
Total Assets 33.662 45.565 37.799 47.516 40.614
Property/Plant/Equipment, Total - Net 0.141 0.121 0.1 0.079 0.049
Goodwill, Net 1.034 1.034 1.034 1.034 1.034
Intangibles, Net 1.809 1.752 1.697 1.641 1.586
Other Long Term Assets, Total 0.239 0.227 0.235 0.168 0.253
Total Current Liabilities 3.515 4.67 3.076 4.55 4.01
Accounts Payable 0.585 0.575 0.815 0.841 0.418
Accrued Expenses 2.93 4.095 2.261 3.709 3.592
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 3.574 4.711 3.099 19.474 19.181
Total Long Term Debt 0 0 0 14.92 15.171
Other Liabilities, Total 0.059 0.041 0.023 0.004 0
Total Equity 30.088 40.854 34.7 28.042 21.433
Redeemable Preferred Stock 0
Common Stock 0.076 0.079 0.079 0.079 0.079
Additional Paid-In Capital 98.441 120.515 121.052 121.545 122.509
Retained Earnings (Accumulated Deficit) -68.433 -79.744 -86.435 -93.586 -101.159
Other Equity, Total 0.004 0.004 0.004 0.004 0.004
Total Liabilities & Shareholders’ Equity 33.662 45.565 37.799 47.516 40.614
Total Common Shares Outstanding 6.14992 9.45222 9.45354 9.45354 9.47358
Total Preferred Shares Outstanding 0 0
Total Receivables, Net 0.151 0.153 0
Long Term Debt 14.92 15.171
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Net income/Starting Line -20.129 -10.583 -12.687 -16.395 -14.73 -33.152
Cash From Operating Activities -29.683 -9.107 -10.623 -15.216 -13.474 -29.44
Cash From Operating Activities 0.188 0.059 0.06 0.031 0.032 0.027
Non-Cash Items 0.978 7.336 0.854 1.198 1.286 2.228
Changes in Working Capital -10.72 -3.091 0.928 -0.273 -0.285 1.234
Cash From Investing Activities 10.608 12.648 -5.125 5.036 -0.017
Capital Expenditures -0.046 -0.046 -0.053 -0.017
Other Investing Cash Flow Items, Total 10.654 12.648 -5.079 5.089
Cash From Financing Activities -0.002 2.001 19.757 17.325 32.68 36.61
Financing Cash Flow Items -0.002 1.937 4.96 12.334 27.87
Issuance (Retirement) of Stock, Net 0 0.064 14.797 4.991 4.81 21.681
Foreign Exchange Effects 0 -0.001 0 0.004 -0.001
Net Change in Cash -19.077 5.541 4.009 7.149 19.189 7.169
Amortization 0.223 0.222 0.223 0.223 0.223
Deferred Taxes -3.051
Issuance (Retirement) of Debt, Net 0 14.929
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line -7.999 -19.31 -26.001 -33.152 -7.573
Cash From Operating Activities -6.452 -15.528 -24.222 -29.44 -6.779
Cash From Operating Activities 0.064 0.127 0.188 0.25
Non-Cash Items 0.565 1.204 1.734 2.228 1.12
Changes in Working Capital 0.918 2.451 -0.143 1.234 -0.386
Cash From Investing Activities 0 0 0
Capital Expenditures 0 0 0
Cash From Financing Activities 0.236 21.674 21.682 36.61 0.095
Issuance (Retirement) of Stock, Net 0.236 21.674 21.682 21.681 0.024
Net Change in Cash -6.216 6.148 -2.541 7.169 -6.685
Financing Cash Flow Items 0 0 0.071
Foreign Exchange Effects 0.002 -0.001 -0.001 -0.001
Issuance (Retirement) of Debt, Net 14.929
Amortization 0.06
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Contrarian Alpha Management, L.L.C. Corporation 14.0862 1367873 1367873 2022-11-18
Francis Capital Management, LLC Hedge Fund 6.1195 594250 253100 2021-12-31 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 3.5869 348313 -2307 2022-09-30 LOW
Shay Capital LLC Hedge Fund 3.5013 340000 -55759 2022-09-30 HIGH
Long Focus Capital Management LLC Hedge Fund 3.174 308220 130624 2022-09-30 MED
Perkins Capital Management, Inc. Investment Advisor 2.246 218100 -10000 2022-09-30 LOW
Wells Fargo Advisors Research Firm 1.4202 137910 13000 2022-09-30 LOW
683 Capital Management LLC Hedge Fund 1.2872 125000 0 2022-09-30 MED
Clearline Capital LP Hedge Fund 1.2367 120094 0 2022-09-30 HIGH
LPL Financial LLC Investment Advisor 1.0288 99900 -1800 2022-09-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.881 85554 0 2022-09-30 LOW
Group One Trading, L.P. Research Firm 0.4373 42461 24247 2022-09-30 HIGH
Renaissance Technologies LLC Hedge Fund 0.3985 38700 -1000 2022-09-30 HIGH
Bencich (John A.) Individual Investor 0.3802 36920 22000 2022-11-18 MED
Citadel Advisors LLC Hedge Fund 0.3604 35000 21725 2022-09-30 HIGH
Diametric Capital Investment Advisor/Hedge Fund 0.3569 34660 15153 2022-09-30 HIGH
QS Investors, LLC Investment Advisor/Hedge Fund 0.3506 34050 33500 2021-06-30 LOW
RBC Capital Markets Wealth Management Research Firm 0.3489 33880 -16520 2022-09-30 LOW
Susquehanna International Group, LLP Investment Advisor 0.3015 29277 -13022 2022-09-30 MED
State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.2339 22716 0 2022-09-30 LOW

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
475000+

Traders

71000+

Active clients monthly

$51000000+

Monthly investing volume

$30000000+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

Achieve Life Sciences, Inc. Company profile

About Achieve Life Sciences Inc

Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in development and commercialization of cytisinicline for smoking cessation and nicotine addiction. The Company’s product candidate, cytisinicline, is a naturally occurring, plant-based alkaloid from the seeds of the Laburnum anagyroides plant. Cytisinicline is structurally similar to nicotine and a mechanism of action that is both agonistic and antagonistic. It is aid in smoking cessation, or nicotine addiction, by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms through agonistic effects on nicotine receptors and by reducing the reward and satisfaction associated with nicotine through antagonistic properties.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Achieve Life Sciences Inc revenues was not reported. Net loss increased from $14.7M to $33.2M. Higher net loss reflects Research & Development increase from $6.5M to $23.3M (expense), General & Administrative increase of 9% to $7.6M (expense), General and administrative increase of 70% to $1.5M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$5.42 to -$4.08.

Equity composition

Common Stock $.001 Par, 04/11, 25M auth., 9,718,251 issd. Insiders own 4.45%. IPO: 10/95, 3,063,750 shares @ $7 by Hambrecht & Quist. *NOTE: All Preferred Stock converted to Common upon completion of IPO. 08/08, Name changed from Sonus Pharmaceuticals, Inc. 08/08, 1-for-18, reverse stock split.

Industry: Biotechnology & Medical Research (NEC)

22722 29Th Dr. Se
Suite 100
SEATTLE
WASHINGTON 98021
US

Income Statement

People also watch

XRP/USD

0.39 Price
-0.420% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 0.00315

BTC/USD

17,088.40 Price
+0.480% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 60.00

Oil - Crude

74.49 Price
-3.930% 1D Chg, %
Long position overnight fee -0.0095%
Short position overnight fee -0.0056%
Overnight fee time 22:00 (UTC)
Spread 0.03

US100

11,577.10 Price
-1.890% 1D Chg, %
Long position overnight fee -0.0172%
Short position overnight fee 0.0062%
Overnight fee time 22:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 475.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading